{
    "clinical_study": {
        "@rank": "112777", 
        "acronym": "DHART", 
        "arm_group": [
            {
                "arm_group_label": "IV artesunate", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)"
            }, 
            {
                "arm_group_label": "IV quinine", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)"
            }
        ], 
        "brief_summary": {
            "textblock": "Delayed anaemia has been reported in European travellers with malaria cured by artesunate.\n      Although no deaths related to this delayed anaemia have been reported so far, blood\n      transfusion has been necessary in some affected patients.  Recent observations suggest that\n      this episodes of anaemia also occurs in endemic countries. The aim of this trial is to\n      assess the incidence of late onset anaemia after treatment with intravenous artesunate\n      compared to intravenous quinine, to identify patients at risk and to clarify the causes of\n      this delayed anaemia."
        }, 
        "brief_title": "Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Anaemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Malaria"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 6 months and \u2264 14 years\n\n          -  Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with\n             asexual forms of P. falciparum or mixed with non-falciparum species\n\n          -  Asexual P. falciparum parasitaemia \u2265 100,000/uL and \u2264500,000/uL\n\n          -  Haemoglobin \u22655.0 g/dL\n\n          -  Parents/guardians agree to hospitalize the child for the length of treatment (3 days)\n             and bring the patient for planned follow-up visits at day 7, 14, 21, 28, 35, 42\n\n          -  Signed consent from the guardian/parents\n\n        Exclusion Criteria:\n\n          -  Body weight \u2264 5 kg\n\n          -  Severe malaria or signs of severe malaria as defined by WHO Guidelines 2013\n\n          -  History of hypersensitivity or contraindication to quinine or artesunate\n\n          -  A clear history of adequate antimalarial treatment in the preceding 24 hours with\n             drugs expected to be effective\n\n          -  Presence of intercurrent illness or any condition which in the judgement of the\n             investigator would place the subject at undue risk or interfere with the patient\n             treatment or results of the study\n\n          -  Participation in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092766", 
            "org_study_id": "KIMORU005"
        }, 
        "intervention": [
            {
                "arm_group_label": "IV artesunate", 
                "intervention_name": "artesunate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IV quinine", 
                "intervention_name": "quinine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Quinine", 
                "Artesunate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "malaria", 
            "anaemia", 
            "artesunate"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "akatshimarie@yahoo.fr", 
                "last_name": "Marie Onyamboko, MD", 
                "phone": "+243990024201"
            }, 
            "facility": {
                "address": {
                    "city": "Kinshasa", 
                    "country": "Congo, The Democratic Republic of the"
                }, 
                "name": "Kinshasa School of Public Health"
            }, 
            "investigator": {
                "last_name": "Marie Onyamboko, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Congo, The Democratic Republic of the"
        }, 
        "number_of_arms": "2", 
        "official_title": "Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: University of Oxford", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Late onset anaemia in this study is defined as a \u226510% drop in haemoglobin on any previous measurement anytime between day 7 and 42", 
            "measure": "Late onset anaemia", 
            "safety_issue": "Yes", 
            "time_frame": "Patients are hospitalized for 4 days or longer if still unwell. After discharge the follow-up consists of 6 weekly visits (time frame 42 days). Late anaemia is measured between 7 and 42 days following the start of antimalarial treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092766"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Oxford", 
        "sponsors": {
            "collaborator": {
                "agency": "Kinshasa School of Public Health", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Oxford", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}